Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.
BACKGROUND
Cancer is associated with an increased risk of thromboembolic diseases, but data on the association between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance.


METHODS
We analysed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which covers over 96% of prostate cancer cases in Sweden. Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and arterial embolism were calculated by comparing observed and expected (using the total Swedish male population) occurrences of thromboembolic disease, taking into account age, calendar-time, number of thromboembolic diseases, and time since previous thromboembolic disease.


RESULTS
Between Jan 1, 1997, and Dec 31, 2007, 30 642 men received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance. 1881 developed a thromboembolic disease. For men on endocrine therapy, risks for DVT (SIR 2.48, 95% CI 2.25-2.73) and pulmonary embolism (1.95, 1.81-2.15) were increased, although this was not the case for arterial embolism (1.00, 0.82-1.20). Similar patterns were seen for men who received curative treatment (DVT: 1.73, 1.47-2.01; pulmonary embolism: 2.03, 1.79-2.30; arterial embolism: 0.95, 0.69-1.27) and men who were on surveillance (DVT: 1.27, 1.08-1.47; pulmonary embolism: 1.57, 1.38-1.78; arterial embolism: 1.08, 0.87-1.33). Increased risks for thromboembolic disease were maintained when patients were stratified by age and tumour stage.


CONCLUSIONS
All men with prostate cancer were at higher risk of thromboembolic diseases, with the highest risk for those on endocrine therapy. Our results indicate that prostate cancer itself, prostate cancer treatments, and selection mechanisms all contribute to increased risk of thromboembolic disease. Thromboembolic disease should be a concern when managing patients with prostate cancer.


BACKGROUND
Swedish Research Council, Stockholm Cancer Society, and Cancer Research UK.
Van Hemelrijck
Mieke
M
King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, UK. mieke.vanhemelrijck@kcl.ac.uk
Adolfsson
Jan
J
Garmo
Hans
H
Bill-Axelson
Anna
A
Bratt
Ola
O
Ingelsson
Erik
E
Lambe
Mats
M
Stattin
Pär
P
Holmberg
Lars
L
D000368:Aged; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy; D012042:Registries; D012307:Risk Factors; D013548:Sweden; D013923:Thromboembolism / Q000453:epidemiology* / Q000209:etiology
Urologe A. 2008 Mar;47(3):270-83
18273599
Stat Med. 1983 Apr-Jun;2(2):267-71
6648141
J Urol. 2008 Dec;180(6):2423-9; discussion 2429-30
18930283
Horm Metab Res. 2006 Apr;38(4):225-9
16700002
Am J Cardiovasc Drugs. 2005;5(3):141-54
15901202
Urology. 1998 May;51(5):775-80
9610591
Vasa. 2009 May;38(2):160-6
19588304
Asian J Androl. 2007 Nov;9(6):751-9
17968460
Urol Int. 2007;79(3):217-25
17940353
Int J Epidemiol. 2001 Oct;30 Suppl 1:S30-4
11759848
Scand J Soc Med. 1993 Mar;21(1):3-9
8469941
J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9
14671159
Thromb Res. 2009;123 Suppl 4:S11-7
19303496
Eur Urol. 2007 Jan;51(1):130-5; discussion 136
16942832
Eur J Cancer. 2008 Mar;44(5):718-25
18207733
Semin Thromb Hemost. 2007 Feb;33(1):80-6
17253194
Maturitas. 1996 Jul;24(3):147-55
8844628
Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21
12814981
IARC Sci Publ. 1987;(82):1-406
3329634
Acta Oncol. 2009;48(1):27-33
18767000
Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82
10207628
Eur J Heart Fail. 2005 Aug;7(5):787-91
15916919
Scand J Urol Nephrol. 2009;43(5):342-9
19921977
Lancet. 2008 May 17;371(9625):1710-21
18486743
Arch Intern Med. 2000 Mar 27;160(6):809-15
10737280
CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
4625049
Scand J Urol Nephrol. 2007;41(6):456-77
17934985
Eur J Endocrinol. 2005 Mar;152(3):479-83
15757866
Cancer. 2005 Apr 15;103(8):1615-24
15742331
Invest Urol. 1981 Mar;18(5):355-7
7203959
Eur Urol. 2008 Jan;53(1):134-45
17597288
Cancer. 2007 Oct 1;110(7):1493-500
17657815
Urologe A. 1994 Mar;33(2):172-4
8178414
Am J Epidemiol. 1998 Nov 15;148(10):1012-7
9829874
Thromb Res. 2007;121(1):127-34
17451792
BJU Int. 2007 Jun;99(6):1398-403
17537215
J Physiol Sci. 2008 Jun;58(3):173-7
18445310
Urol Res. 1981;9(1):25-8
6455833